The US FDA has clarified when sponsors are eligible for 180-day marketing exclusivity in a letter to applicants of abbreviated new drug applications for generic versions of Indivior PLC's Suboxone (buprenorphine/naloxone) sublingual film.
Specifically, the agency provided a new definition of "first applicant," whereby a sponsor does not lose this status by failing to provide timely notice of paragraph IV certification, and applied the